Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acebilustat mass balance study in healthy males
NCT03964558Phase 1Completed
- Sponsor
- Celtaxsys, Inc.
- Start
- Apr 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of acebilustat in cystic fibrosis (CF), sponsored by Celtaxsys, Inc. Primary endpoint: Mass balance recovery of total radioactivity in all excreta at Day 10. Started Apr 2019; status: completed.
02
Drugs
acebilustat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03964558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964558.